Skip to main content

Currently Skimming:

Appendix: Workshop Statement of Task and Agenda
Pages 51-54

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 51...
... , Medicare reimbursement policies and the legislative limitations on those policies, and state laws prohibiting restrictions on oncology drug prescribing; • Cancer drug distribution channels and access programs, such as the  340B program and co-pay assistance programs; and • Changing economics of oncology practice and the historic reliance  on office-based drug prescribing for revenues. The committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions.
From page 52...
... Bach, Memorial Sloan Kettering Cancer Center Planning Committee Chair 8:15 am Session 1: Trends in Oncology Care Moderator: Barry Fortner, ION Solutions Escalating drug prices • Kalipso Chalkidou, NICE International (via phone) Consolidation of practices into hospital partnerships/ changing landscape of oncology practice • Bruce Gould, Community Oncology Alliance The financial toxicity of cancer treatment: Can patients cope with costs?
From page 53...
... generics • Jeffrey Peppercorn, Duke University Medical School Oral vs. IV drugs • Lee Newcomer, UnitedHealth Group 340B vs.
From page 54...
... 54 ENSURING PATIENT ACCESS TO AFFORDABLE CANCER DRUGS 3:00 pm Session 3: Value and Policy Options Moderator: Scott Ramsey, Fred Hutchinson Cancer Center The patient perspective •  helley Fuld Nasso, National Coalition for Cancer S Survivorship Value-based insurance design •  ark Fendrick, University of Michigan Center for Value M Based Insurance Design Bundling of payments •  homas Feeley, The University of Texas MD Anderson T Cancer Center Value-based drug pricing •  atricia Danzon, Wharton School, University of P Pennsylvania Lessons from the Health Evidence Review Commission, Oregon Health Authority • Kevin Olson, Providence Cancer Center Panel Discussion 5:30 pm Adjourn

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.